SCSi Yuan Chew

Si Yuan Chew

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Si Yuan Chew has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Disproportionate Burden of Cardiovascular Disease in Mild-to-Moderate COPD

    by Wen Zhang, Jian Wen, Si Yuan Chew, Yiyue Hao, Fei Liao, Mariko Siyue Koh, Zhi Xu, Guansong Wang, Xia Wang, Pei Yee Tiew

    Background: Cardiovascular disease (CVD) is a major comorbidity in chronic obstructive pulmonary disease (COPD). However, whether cardiovascular burden increases with the severity of COPD requires more nuanced investigation. This study investigated the association between COPD severity and CVD prevalence, and evaluated their independent and joint effects on long-term survival. Methods: This multicenter cohort study included 553 stable COPD patients. Disease severity was stratified by GOLD grades and the multidimensional BODEx index. Logistic regression and Cox proportional hazards models were used to evaluate CVD prevalence across severity stages and identify predictors of all-cause mortality. Results: Patients were classified as mild-to-moderate (GOLD 1– 2; 57.7%) or severe-to-very severe (GOLD 3– 4; 42.3%). A clear paradox emerged: CVD prevalence was significantly lower in severe-to-very severe COPD compared to mild-to-moderate disease (45.7% vs. 59.6%, P=0.001). Adjusted analysis indicated that severe airflow limitation was independently associated with lower odds of CVD (OR 0.68, P=0.038). Notably, CVD was a significant mortality predictor only in early-stage disease. Conversely, in advanced COPD, the multidimensional BODEx score > 4 emerged as the strongest independent predictor of mortality (HR 2.19, P< 0.001), rendering CVD history statistically non-significant (P=0.10). Conclusion: CVD burden is highest in mild-to-moderate stages, where it significantly drives mortality. In advanced disease, overall multidimensional severity (BODEx index) supersedes CVD to determine survival. These findings emphasize prioritizing early cardiovascular screening in mild COPD while utilizing multidimensional indices for advanced prognosis.

  • Open Access

    Predictors of Clinical Stability and Mortality in COPD: A Longitudinal Study

    by Wesley Teck Wee Loo, Si Yuan Chew, Jessica Han Ying Tan, Rui Ya Soh, Mariko Siyue Koh, Therese S Lapperre, Pei Yee Tiew

    Background: There is no consensus on the definition of clinical stability in chronic obstructive pulmonary disease (COPD), and it is less frequently used as a treatment target compared to severe asthma. The factors that determine clinical stability and their effects on mortality are less well-studied in patients with COPD. Methods: To address this gap, we conducted a prospective longitudinal cohort study to identify predictors of two-year clinical stability, defined as no exacerbations and stable symptoms (< 2 point change in CAT score from baseline), and the impact of comorbid cardiovascular disease (CVD) on clinical stability and mortality in COPD patients. Results: A total of 463 patients (mean age 71 ± 9 years) were enrolled in this study. The cohort was predominantly Chinese (81.7%) and 45.6% of participants were current smokers. The majority (55.7%) had a history of CVD. Approximately 36% of the cohort achieved clinical stability at one year, and one-third achieved stability at two years. Predictors of 2-year clinical stability included higher body mass index (BMI) (p< 0.001), higher post-bronchodilator FEV1/FVC ratio (p=0.0132), fewer baseline exacerbations (p=0.007), absence of bronchiectasis (p=0.045), preserved hemoglobin levels (p=0.019), and successful smoking cessation (p=0.039). Notably, while 2-year clinical stability did not predict subsequent mortality, the presence of CVD was a significant predictor of 5-years mortality (HR 1.48, 95% CI 0.99– 2.22; p=0.05). Conclusion: Our study identified several predictors of 2-year clinical stability in patients with COPD. However, clinical stability at 2 years did not predict subsequent mortality. These findings suggest that clinical stability and mortality are distinct outcomes that are driven by different sets of predictive variables. This underscores the need for a comprehensive approach to COPD management that not only addresses exacerbations and symptoms, but also considers a broader range of factors influencing survival, particularly the management of comorbidities such as cardiovascular disease.


  • Can a Bayesian approach clarify if corticosteroids are beneficial for severe community-acquired pneumonia?

    by Wesley Teck Wee Loo, Kendra Jing Ying Tang, Si Yuan Chew

    Despite advances in the antimicrobial treatment of sepsis and organ support in the intensive care unit (ICU), community-acquired pneumonia (CAP) remains a leading cause of mortality and disability-adjusted life years lost globally.1 Severe CAP, where CAP becomes complicated by acute hypoxaemic respiratory failure or shock, is also the most common cause of sepsis, where complex and heterogeneous biological mechanisms underlie a dysregulated inflammatory host response that ultimately leads to major organ dysfunction and death. Along with the emerging threats of respiratory pandemics, antimicrobial resistance, ageing populations and the rise of chronic diseases, much research has been conducted to improve the treatment outcomes of CAP via host immunomodulation. These efforts have focused almost exclusively on anti-inflammatory effects of corticosteroids, which have a proven track record of improving outcomes in other forms of sepsis, such as bacterial meningitis, Pneumocystis jirovecii pneumonia and severe COVID-19.

  • Pulmonary sclerosing pneumocytoma – approaching a solitary pulmonary nodule and the limitations of risk prediction models

    by Kundan Reddy Saripalli, Mark Qi Wei Wang, Chun Yuen Chow, Si Yuan Chew

    Our case is an asymptomatic, non-smoking, East Asian woman in her 40s presenting with a solitary pulmonary nodule (SPN). On imaging, the 1.7 cm solid SPN located in the left upper lobe, was rounded in morphology and moderately fluorodeoxyglucose avid. The clinical pretest probability of malignancy assessed by risk prediction models such as Brock (19.1%), Mayo Clinic (56.2%) and Herder (51.4%) was discordant. She underwent a percutaneous CT-guided needle biopsy, establishing a diagnosis of pulmonary sclerosing pneumocytoma (PSP). PSP is a rare benign lung neoplasm with indolent growth characteristics that has been described predominantly in non-smoking women. Our case illustrates the limitations of applying existing risk prediction models in Asia where the epidemiology and biology of lung cancer differ significantly from the Caucasian derivation cohorts. Additionally, the risk models do not account for tuberculosis, which is endemic in Asia and can mimic malignancy. Non-surgical lung biopsy remains useful in minimising unnecessary thoracotomy.


  • Inferior vena cava filter migration due to guidewire ensnarement during peripherally inserted central catheterisation

    by Si Y Chew, Huey Y Lim, Heng A Ong, Vikram Vijayan Sannasi, Bernard Wee, Chee K Tan, Amit Kansal

  • Open Access

    Improving asthma care with Asthma-COPD Afterhours Respiratory Nurse at Emergency (A-CARE)

    by Si Yuan Chew, Jenneth Yue Ling Leow, Adrian Kok Wai Chan, Jing Jing Chan, Kenneth Boon Kiat Tan, Butta Aman, Donna Tan, Mariko Siyue Koh

    Background Emergency departments (ED) are important providers of asthma care, particularly after-hours. We identified gaps for quality improvement such as suboptimal adherence rates to three key recommendations from the Global Initiative for Asthma (GINA) guidelines for discharge management asthma guidelines. These were: the prescription of oral and inhaled corticosteroids (OCS and ICS) and issuance of outpatient follow-up for patients discharged from the ED. Aim To achieve an adherence rate of 80% to GINA guidelines for ED discharge management by providing after-hours asthma counselling services. Methods We implemented Asthma-COPD Afterhours Respiratory Nurse at Emergency (A-CARE) according to the Plan-Do-Study-Act (PDSA) framework to provide after-hours asthma counselling and clinical decision support to ED physicians three nights a week. Data on adherence rates to the GINA guidelines were collected and analysed on a run chart. Results After 17 months’ follow-up, a sustained improvement was observed in patients reviewed by A-CARE in the median adherence rates to OCS prescription (58% vs 86%), ICS initiation (27% vs 67%) and issuance of follow-up (69% vs 92%), respectively. The overall impact was, however, limited by a suboptimal referral rate to A-CARE (16%) in a clinical audit of all ED patients with asthma. Nonetheless, in this audit, attendance rates for patients referred to our respiratory department for follow-up were higher in those receiving asthma counselling compared with those who did not (41.7% vs 15.9%, p=0.0388). Conclusion Sustained improvements in the adherence rates to guidelines were achieved for patients reviewed by A-CARE but were limited in overall impact due to suboptimal referral rate. We plan to improve the quality of asthma care by implementing further PDSA cycles to increase the referral rates to A-CARE.


  • A 78-Year-Old Man With Recurrent Hemoptysis and Persistent Pulmonary Nodule

    by Si Yuan Chew, Chien Sheng Tan, Youxin Puan, Jansen Meng Kwang Koh


  • Open Access

    VIEKIRA PAK associated drug-induced interstitial lung disease: Case series with systematic review of literature

    by Yu Jun Wong, Si Yuan Chew, John Chen Hsiang, Prem Harichander Thurairajah, Rahul Kumar, Eng Kiong Teo, Roshni Sadashiv Gokhale, Imran Bin Mohamed Noor, Jessica Tan


  • Making Clinical Practice Guidelines Pragmatic: How Big Data and Real World Evidence Can Close the Gap

    by Si Yuan Chew, Mariko S Koh, Chian Min Loo, Julian Thumboo, Sumitra Shantakumar, David B Matchar

    Clinical practice guidelines (CPGs) have become ubiquitous in every field of medicine today but there has been limited success in implementation and improvement in health outcomes. Guidelines are largely based on the results of traditional randomised controlled trials (RCTs) which adopt a highly selective process to maximise the intervention’s chance of demonstrating efficacy thus having high internal validity but lacking external validity. Therefore, guidelines based on these RCTs often suffer from a gap between trial efficacy and real world effectiveness and is one of the common reasons contributing to poor guideline adherence by physicians. “Real World Evidence” (RWE) can complement RCTs in CPG development. RWE—in the form of data from integrated electronic health records—represents the vast and varied collective experience of frontline doctors and patients. RWE has the potential to fill the gap in current guidelines by balancing information about whether a test or treatment works (efficacy) with data on how it works in real world practice (effectiveness). RWE can also advance the agenda of precision medicine in everyday practice by engaging frontline stakeholders in pragmatic biomarker studies. This will enable guideline developers to more precisely determine not only whether a clinical test or treatment is recommended, but for whom and when. Singapore is well positioned to ride the big data and RWE wave as we have the advantages of high digital interconnectivity, an integrated National Electronic Health Record (NEHR), and governmental support in the form of the Smart Nation initiative. Key words: Guideline adherence, Real world data, Physicians' practice patterns